1. Rosiglitazone 011 Study Group. Rosiglitazone (BRL49653) monotherapy has significant glucose lowering effect in type 2 diabetic patients;Patel;Diabetes,1998
2. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer in humans;Cox;Drug Metab Dispos,2000
3. Rosiglitazone decreases insulin resistance and improves beta-cell function in patients with type 2 diabetes;Matthews;Diabetologica,1999
4. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ);Lehmann;J Biol Chem,1995
5. Thiazolidinediones produce a confirmational change in peroxisomal proliferator-activated receptor-γ; binding and activation correlate with antidiabetic actions in db/db mix;Berger;Endocrinology,1996